Recommended

New webinar with Fujifilm: Monocyte activation test (MAT): Insight into examining regulations and markets prospects
New webinar: The path to optimisation in pharmaceutical microbiology
Join our webinar: An alternative medium to support sterility testing using the Growth Direct® Rapid Sterility System
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps
reference

Beyond nutrition: vitamins and n-3 polyunsaturated fatty acids as APIs

Posted: 23 October 2019 | | No comments yet

References for ‘Beyond nutrition: vitamins and n-3 polyunsaturated fatty acids as APIs’, in European Pharmaceutical Review issue 5 2019.

References 

  1. World Health Organization: Cardiovascular Diseases, October 2019 (http://www.who.int/mediacentre/factsheets/fs317/en/).
  2. Baker W, et al. Meta-analysis of ascorbic acid for prevention of postoperative atrial fibrillation after cardiac surgery. Am J Health Syst Pharm. 2016;73: 2056–2066.
  3. Cahill L, et al. Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol. 2013;61: 728-737.
  4. Cahill L, et al. The risk of coronary heart disease associated with glycosylated hemoglobin of 6.5% or greater is pronounced in the haptoglobin 2-2 genotype. J Am Coll Cardiol. 2015;66: 1791–1799.
  5. Home B, et al. Haptoglobin 2-2 genotyping for refining standard cardiovascular risk assessment: A promising proposition in need of validation. J Am Coll Cardiol 2015;66: 1800–1802.
  6. Milman U, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: A prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008;28: 341–347.
  7. Blum S, et al. Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arterioscler Thromb Vasc Biol. 2008;28: 18–20.
  8. Ferlay J, et al. Cancer incidence and mortality patterns in Europe : Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103: 356-387.
  9. World Health Organization: Cancer Data and Statistics, October 2019 (http://www.euro.who.int/en/health-topics/noncommunicable-diseases/cancer/data-and-statistics).
  10. Carr A, et al. The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life. Front Oncol. 2014;4.
  11. Ma Y, et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6: 222.
  12. Cieslak J, et al. Treatment of pancreatic cancer with pharmacological ascorbate. Curr Pharm Biotechnol. 2015;16: 759– 770.
  13. J Du, et al. Pharmacological ascorbate radio sensitizes pancreatic cancer. Cancer Res. 2015;75: 3314–3326.
  14. Lee A, et al. Injectable hydrogels from triblock copolymers of vitamin E-functionalized polycarbonate and poly(ethylene glycol) for subcutaneous delivery of antibodies for cancer therapy. Adv Funct Mater. 2014;24: 1538–1550.
  15. Lee A, et al. Injectable biodegradable hydrogels from vitamin D-functionalized polycarbonates for the delivery of Avastin with enhanced therapeutic efficiency against metastatic colorectal cancer. Biomacromolecules. 2015;16: 465–475.
  16. World Health Organization: Diabetes Data and Statistics, October 2019 (http://www.euro.who.int/en/health-topics/noncommunicable-diseases/diabetes/data-and-statistics).
  17. Bhatt D, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380: 11-22.
  18. Wu C, et al. Vitamin D supplementation and glycemic control in type 2 diabetes patients: A systematic review and meta-analysis. Metab Clin Exp. 2017;73: 67–76.
  19. Upadhyay J, et al. Pharmacotherapy of type 2 diabetes: An update. Metab Clin Exp. 2018;78: 13–42.
  20. Carmel R, et al. How I treat cobalamin (vitamin B12) deficiency. 2008;112: 2214–2221.
  21. Strong A, et al. Sublingual vitamin B12 compared to intramuscular injection in patients with type 2 diabetes treated with metformin: a randomised trial. N Z Med J. 2016; 129:67–75.
  22. Rabbani N, et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double blind placebo-controlled pilot study. 2009;52: 208–212.
  23. Polizzi F, et al. Increased DNA-glycation in type 2 diabetic patients: The effect of thiamine and pyridoxine therapy. Exp Clin Endocrinol 2012;120: 329–334.
  24. Shahmiri F, et al. High-dose thiamine supplementation improves glucose tolerance in hyperglycemic individuals: a randomized, double-blind crossover trial. Eur J Nutr. 2013;52: 1821–1824.
  25. Alaei-Shahmiri F, et al. The impact of thiamine supplementation on blood pressure, serum lipids and C-reactive protein in individuals with hyperglycemia: a randomised, double-blind cross-over trial. Diabetes Metab Syndr Clin Res Rev. 2015;9: 213–217.
  26. Mimenza Alvarado A. Clinical trial assessing the efficacy of gabapentin plus B complex (B1/B12) versus pregabalin for treating painful diabetic neuropathy. J Diabetes Res. 2016:4078695.
  27. Alexander D, et al. A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk. Mayo Clinic Proceedings. 2017;92(1):15-29.
  28. Colomer R, et al. N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr. 2007;97(5): 823-31.
  29. Raats M, et al. Food for the ageing population. Woodhead Publishing Limited 2009.
  30. Nabavi S, et al. Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials. Cancer Metastasis Rev 2015;34(3): 359-80.